



FOR IMMEDIATE RELEASE

Contact: Andy Lee - Vincere Biosciences
Phone: 857-245-9492
Email: Lee@VincereBio.com

Vincere Biosciences Welcomes Dario Alessi, Stephen K. Burley, and Peter Lansbury to Scientific Advisory Board

Cambridge, MA, USA - July 2019: [Vincere Biosciences, Inc.](#), a Delaware corporation headquartered in Cambridge, MA is excited to announce initial formation of its Scientific Advisory Board with a stellar group of experts in key areas critical to the success of Vincere's mission to develop small molecule therapeutics that stop the progression of Parkinson's disease.

Dario Alessi, PhD is Director of the Medical Research Council Protein Phosphorylation and Ubiquitylation unit at University of Dundee. Alessi has spent decades characterizing how phosphorylation and ubiquitylation cascades control biological function and disease resulting in 275 manuscripts which have been cited over 70,000 times establishing his role as a leader of the field. His expertise will be invaluable toward assay design to understand and probe the complex biology of these targets.



Stephen K. Burley, MD, DPhil is professor and Chair, Founding Director of the Institute for Quantitative Biomedicine, and Director of the RCSB Protein Data Bank at Rutgers. Previously he was Distinguished Lilly Research Scholar in Lilly Research Laboratories, which he joined upon acquisition of SGX Pharmaceuticals where he was CSO after SGX acquisition of Prospect Genomics, which he co-founded. Prior to Prospect, Burley was Professor at The Rockefeller University and an Investigator in the Howard Hughes Medical Institute. His structural biology background will aid Vincere's efforts to design and optimize compounds for new targets.



Peter Lansbury, PhD is Professor of Neurology at Harvard Medical School where he founded the Laboratory for Drug Discovery in Neurodegeneration and directed the Morris K. Udall NIH Parkinson's Disease Research Center of Excellence at Brigham and Women's Hospital. Previously he was Professor of Chemistry at MIT, and Founder and CSO of Link Medicine through its sale to AstraZeneca. Currently CSO at Lysosomal Therapeutics, Inc. developing disease modifying therapies for Parkinson's disease, Lansbury brings both deep expertise in enzymology and Parkinson's disease biology, as well as direct experience advancing a small molecule CNS program through pharma partnership and into the clinic.



About Vincere Biosciences Inc: Vincere Biosciences was founded in 2018 and develops therapeutics for neurodegenerative disease empowered by a unique suite of computational tools coupled with traditional biology and drug discovery expertise. Vincere is Latin for “To win” a constant reminder of our mission to win the fight against disease. <http://www.vincerebio.com>